Lloyd Segal
Chief Executive Officer at REPARE THERAPEUTICS INC.
Net worth: 2 M $ as of 30/11/2022
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Todd Foley | M | 52 |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | 7 years |
Brian Goodman | M | - |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | - |
Ian Aitken | M | - |
Pembroke American Growth Fund, Inc.
Pembroke American Growth Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada. | 15 years |
Matt Roden | M | 53 |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | 4 years |
Carol Schafer | F | 60 | 5 years | |
David Bonita | M | 48 | 5 years | |
Bhupinder Brar | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | - |
Anthony Calzetta | M | - |
Pembroke American Growth Fund, Inc.
Pembroke American Growth Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada. | - |
Samarth Kulkarni | M | 45 | 5 years | |
Thomas Civik | M | 55 | 3 years | |
Susan Molineaux | M | 70 | 1 years | |
Briggs Morrison | M | 65 | 7 years | |
Ann Rhoads | F | 58 | 4 years | |
Dirk Alkema | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 17 years |
Steve Forte | M | 45 | 5 years | |
David Rosen | M | - | - | |
Shulamit Ron-Bigger | M | - |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | 2 years |
Lloyd Segal | M | - |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | - |
Kim Seth | M | - | 7 years | |
Keith Tucker | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 7 years |
Michael Zinda | M | 53 | 5 years | |
Philip Herman | M | - | 2 years | |
Joel Drewry | M | - |
Versant Ventures Canada Ltd.
| 6 years |
Maria Koehler | M | 67 | 5 years | |
Linda Griego | F | 76 |
The Growth Fund of America
| - |
Helen Kim | F | 61 |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | 2 years |
Caroline Miller | F | - |
Pembroke American Growth Fund, Inc.
Pembroke American Growth Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada. | 5 years |
Glen Roane | M | 67 |
Pembroke American Growth Fund, Inc.
Pembroke American Growth Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada. | 16 years |
Johan Vandersande | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 8 years |
Ian Mumford | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 8 years |
John M. Langstaff | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 8 years |
Jeff Tory | M | - |
Pembroke American Growth Fund, Inc.
Pembroke American Growth Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada. | - |
Robin T. Garner | F | - | - | |
John Freund | M | 70 |
The Growth Fund of America
| - |
Leonade D. Jones | F | 76 |
The Growth Fund of America
| - |
Brian Harold Hadfield | M | 71 |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | - |
Oleg Nodelman | M | 47 |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | - |
Gabriel de Alba | M | 51 |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 17 years |
Michael McLaughlin | M | - |
Pembroke American Growth Fund, Inc.
Pembroke American Growth Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada. | - |
Daniel Bélanger | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jerel Davis | M | 47 | 7 years | |
Guthrie Stewart | M | 68 |
Pembroke American Growth Fund, Inc.
Pembroke American Growth Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada. | 12 years |
Nicholas Green | M | 60 |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 9 years |
Raidy Kevin J. | M | 55 | 1 years | |
Newton G. Z. Glassman | M | 60 |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | - |
David A. Long | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 5 years |
Philippe Couillard | M | 67 |
Persistence Capital Partners LP
| 2 years |
David N. Bell | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 13 years |
Mary Haak-Frendscho | M | 67 |
Versant Ventures Canada Ltd.
| 2 years |
Katina Dorton | F | 66 | 1 years | |
Raj Puri | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 10 years |
Dina Iezzi | F | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 11 years |
Daniel Durocher | M | - | - | |
Agnel Sfeir | M | - | - | |
Frank Sicheri | M | - | - | |
Safa'a Al-Rais | M | - |
Therapure Biopharma, Inc.
Therapure Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada. | 11 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 46 | 82.14% |
United States | 10 | 17.86% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lloyd Segal
- Personal Network